Background Primaquine is essential for the radical cure of vivax malaria, however its broad
application is hindered by the risk of drug-induced haemolysis in individuals with glucose-6 …

Safe treatment of Plasmodium vivax requires diagnosis of both the infection and status of
erythrocytic glucose-6-phosphate dehydrogenase (G6PD) activity because hypnozoitocidal …

Primaquine and other 8-amnoquinoline based anti-malarials can cause haemolysis in
subjects with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Correct diagnosis of …

Radical cure of Plasmodium vivax malaria in glucose-6-phosphate dehydrogenase (G6PD)
deficient individuals employs weekly primaquine dosing. This is the only recommended …

BACkGROunD Primaquine is currently the only medicine for treating relapses of
Plasmodium vivax and P. ovale malaria, due to its specific activity against malaria …

Glucose-6-phosphate dehydrogenase deficiency (G6PDd) is the most common
enzymopathy globally, and deficient individuals may experience severe hemolysis following …

Background Wide-spread implementation of treatment regimens for the radical cure of vivax
malaria is hindered by a range of factors. This has resulted in an increase in the relative …

Malaria elimination will be possible only with serious attempts to address asymptomatic
infection and chronic infection by both Plasmodium falciparum and Plasmodium vivax …

Background Patients infected by Plasmodium vivax or Plasmodium ovale suffer repeated
clinical attacks without primaquine therapy against latent stages in liver. Primaquine causes …

The widespread use of primaquine (PQ) radical cure for P. vivax, is constrained by concerns
over its safety. We used routinely collected patient data to compare the overall morbidity and …